Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study

Background. Currently, targeted therapy is the most promising for the treatment of myelofibrosis (MF). Today, the results of many years of experience with the use of ruxolitinib, including outside randomized trials and the identification of predictors of its effectiveness are important.Aim. To evalu...

Full description

Bibliographic Details

Published in:	Онкогематология
Main Authors:	O. Yu. Vinogradova, M. M. Pankraskina, A. L. Neverova, D. I. Shikhbabaeva, M. A. Murzabekova, M. V. Chernikov, A. V. Popova, V. P. Kosenkova, L. B. Egoryan, V. V. Ptushkin
Format:	Article
Language:	Russian
Published:	ABV-press 2024-09-01
Subjects:	myeloproliferative neoplasm myeloproliferative disease myelofibrosis primary myelofibrosis postthrombocythemic myelofibrosis post-polycythemic myelofibrosis jak2 v617f targeted therapy ruxolitinib
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/934